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ABSTRACT: Four natural lactylates of chlorinated fatty acids,
chlorosphaerolactylates A−D (1−4), were isolated from the
methanolic extract of the cyanobacterium Sphaerospermopsis sp.
LEGE 00249 through a combination of bioassay-guided and MS-
guided approaches. Compounds 1−4 are esters of (mono-, di-, or
tri)chlorinated lauric acid and lactic acid, whose structures were
assigned on the basis of spectrometric and spectroscopic methods
inclusive of 1D and 2D NMR experiments. High-resolution mass-
spectrometry data sets also demonstrated the existence of other
minor components that were identified as chlorosphaero(bis)-
lactylate analogues. The chlorosphaerolactylates were tested for
potential antibacterial, antifungal, and antibiofilm properties using
bacterial and fungal clinical isolates. Compounds 1−4 showed a weak inhibitory effect on the growth of Staphylococcus aureus S54F9
and Candida parapsilosis SMI416, as well as on the biofilm formation of coagulase-negative Staphylococcus hominis FI31.
Over the past few decades, cyanobacteria have beenconsidered as one of the most promising groups of
bacteria for natural products discovery.1,2 Owing to the distinct
ecological niches that these organisms occupy and their
particular ecophysiology, natural products synthesized by
cyanobacteria are diverse and structurally unique.3 These
metabolites can be peptides, polyketides, derivatives of fatty
acids, and hybrids thereof, many featuring unusual modifica-
tions such as halogenation.4 More than 5000 halogenated
compounds have been isolated from natural sources including
bacteria, fungi, algae, higher plants, invertebrates, and
vertebrates from distinct environments.5,6 Furthermore, the
presence of halogen substituents (such as chlorine, bromine,
and more rarely iodine and fluorine) in natural products
influences their biological activity,7 representing a valuable and
expanding class of natural products. In the past years, several
halogenated fatty acids amide derivatives were isolated from
marine cyanobacteria including the malyngamides,8 the
jamaicamides,9 the grenadamides,10 and the columbamides.11
These compounds have been associated with biological
activities such as cytotoxicity, calcium and sodium channel
modulation, and cannabinoid receptor binding. Additional
examples of halogenated fatty acids incorporated in natural
peptides can be found in the literature, such as the
puwainaphycins originating from a terrestrial cyanobacterium12
or lyngbyabellin extracted from the marine cyanobacterium
Lyngbya majuscula.13 Moreover, an unusual and fascinating
class of chlorosulfolipids was reported in a Nostoc sp. strain,14
and more recently aranazoles, extensively polychlorinated
compounds were described in a Fischerella sp. strain,15 proving
once again the wide structural diversity of halogenated
metabolites that cyanobacteria are capable of producing.
Our current interest in identifying new cyanobacterial
metabolites with antibiotic and antibiofilm activity in the
framework of the NoMorFilm project16 led us to investigate
the chemical diversity of cyanobacterial strains from the Blue
Biotechnology and Ecotoxicology Culture Collection, LEGE-
CC (based at CIIMAR). Through a bioassay-guided approach,
Sphaerospermopsis sp. LEGE 00249 was pinpointed as a
promising producer of antibiofilm and antibacterial metabo-
lites. This cyanobacterial strain was isolated from a Portuguese
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freshwater reservoir and was previously reported as a producer
of a prenylated cyanobactin, a cyclic peptide produced by
ribosomal synthesis.17 Herein, we describe the detection,
isolation, structure elucidation, and bioactivity of four new
lactylates of chlorinated fatty acids of cyanobacterial origin, the
chlorosphaerolactylates A−D (1−4). Moreover, detection of
masses corresponding to compounds of the chlorosphaer-
olactylate type or chlorosphaerobislactylate type is also
reported.
■ RESULTS AND DISCUSSION
We have recently reported a preliminary screening assay for
inhibition of microbial biofilm formation by cyanobacterial
organic extracts.16 From the screening assay the methanolic
extract of the strain Sphaerospermopsis sp. LEGE 00249 was
selected as promising for isolation of active compounds
(minimum bactericidal concentration; MBC < 4.6 mg/mL).
This cyanobacterial strain was regrown (50 L laboratory scale),
and its biomass was sequentially extracted with hexane, EtOAc,
and MeOH; the latter was submitted to bioassay-guided
fractionation, assisted by HPLC, on the basis of the growth
Figure 1. Bioassay-guided discovery of antibacterial compounds. Schematic representation of a 96-well plate containing active fractions: (A)
microbial sediments obtained after the microdilution antibiotic susceptibility test; (B) result of the bactericidal assay after the upper wells were
subcultured onto a solid agar medium (MSA). Inhibition of S. aureus S54F9 growth was observed in fractions F32, F34−38, F40, F41, F43−F48.
The groups G1−G6 were defined according to their chemical composition after HRESIMS analyses.
Chart 1
Table 1. 1H NMR (600.13 MHz) and 13C NMR (150.9 MHz) Spectroscopic Data (δ in ppm) for Compounds 1−4
chlorosphaerolactylate A (1) chlorosphaerolactylate B (2) chlorosphaerolactylate C (3) chlorosphaerolactylate D (4)
position δC, type δH (J in Hz) δC, type δH (J in Hz) δC, type δH (J in Hz) δC, type δH (J in Hz)
1 175.1,a C 176.5,a, C 175.6,a C 178.7,a C
2 70.3, CH 4.99, q (7.2) 71.2, CH 4.99, q (7.1) 70.6, CH 4.99, q (7.1) 72.7, CH 4.91, q (7.1)
3 17.4, CH3 1.46, d (7.2) 17.7, CH3 1.44, d (7.1) 17.6, CH3 1.45, d (7.1) 18.2, CH3 1.42, d (7.1)
1′ 174.7, C 175.1, C 174.7, C 175.1, C
2′ 34.6, CH2 2.40, m 34.9, CH2 2.37, m 34.7, CH2 2.41, m 34.9, CH2 2.4, m
3′ 25.4, CH2 1.65, m 25.9, CH2 1.62, m 25.4, CH2 1.64, m 25.4, CH2 1.64, m
1.67, m
4′ 27.0, CH2 1.48, m 30.2, CH2 1.35, m 27.0, CH2 1.49, m 27.1, CH2 1.47, m
1.59, m 1.59, m 1.57, m
5′ b 39.3, CH2 1.69, m 30.4, CH2 1.33, m 39.3, CH2 1.68, m 39.3, CH2 1.69, m
5′ a 1.77, m 1.78, m 1.78, m
6′ 64.8, CH 3.93, m 30.5b/30.6,b CH2 1.32, m 64.9, CH 3.92, m 64.8, CH 3.94, m
7′ b 39.5, CH2 1.69, m 1.32, m 39.7, CH2 1.66, m 39.4, CH2 1.69, m
7′ a 1.77, m 1.76, m 1.78, m
8′ b 27.4, CH2 1.48, m 1.32, m 30.0, CH2 1.32, m 27.3, CH2 1.45, m
8′ a 1.56, m 1.56, m
9′ b 29.5, CH2 1.35, m 30.0, CH2 1.34, m 27.5, CH2 1.42, m 29.1, CH2 1.38, m
9′ a 1.37, m 1.53, m
10′ 27.8, CH2 1.46, m 27.9, CH2 1.44, m 32.9, CH2 1.30, m 26.9, CH2 1.57, m
11′ 33.7, CH2 1.77, m 33.8, CH2 1.75, m 23.6, CH2 1.33, m 44.7, CH2 2.19, m
12′ 45.7, CH2 3.56, t (6.7) 45.7, CH2 3.55, t (6.6) 14.4, CH3 0.91, t (7.0) 75.0, CH 5.99, t (6.1)
aBroad signal. bCould not be assigned unambiguously. All spectra recorded in CD3OD.
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inhibition of the clinical isolate Staphylococcus aureus S54F918
(Figure S1). The MBC was calculated for some of the active
fractions (Figure 1): F37 < 16.6 mg/mL, F40 < 5.2 mg/mL,
F43 < 6.4 mg/mL, and F45 < 10 mg/mL.
Analysis of the active fractions by HRESIMS yielded six
groups (G1−G6; Figure 1) that were defined according to
their chemical composition. The presence of various mass
peaks showing typical chlorine isotope patterns indicated the
fractions contained compounds bearing one, two, or three
chlorine atoms (Figure S2). More specifically, group G2
presented the isotope pattern at m/z 339/341/343
(100:69.9:11 ratio), consistent with the presence of two
chlorine atoms in the molecule (m/z 339.1117 [M − H]−;
C15H26Cl2O4), and group G3 showed the isotope cluster at m/
z 373/375/377/379 (100:92.8:30.9:3.5 ratio), indicating the
molecule to bear three chlorine substituents (m/z 373.0707
[M − H]−; C15H25Cl3O4). Furthermore, groups G4 and G5
showed an isotope pattern at m/z 305/307 (100:32.7 ratio),
consistent with the presence of only one chlorine atom (m/z
305.1504 [M − H]− and m/z 305.1509 [M − H]−,
respectively; C15H27ClO4). Although G4 and G5 showed
peaks with the same mass, these presented different retention
times (Figure S2), suggesting these molecules to be structural
isomers. Finally, the chlorine isotopic patterns in groups G1
and G6 were of low intensity (close to the baseline), and the
amounts of these compounds were not suitable for NMR
experiments.
The structures of compounds 1−4 were elucidated through
the combination of spectroscopic and spectrometric methods.
They were identified as esters of chlorinated lauric acid and
lactic acid. Nevertheless, the amounts isolated from the 50 L
culture were not enough to establish an unambiguous structure
for compound 4 and to evaluate the antibiofilm activity;
therefore the cyanobacterial strain was regrown using Green
Wall Panel (GWP-III) outdoor photobioreactors. Compounds
1−4 were then isolated from this biomass guided by MS;
however suitable conditions to separate 2 and 3 were not
found, so they were isolated as a mixture.
Compound 1, named chlorosphaerolactylate A, was
obtained as an oil ([α]24D +34.1). The molecular formula
C15H26Cl2O4, consistent with two degrees of unsaturation, was
deduced from the HRESIMS spectrum showing the deproto-
nated molecule mass peak at m/z 339.1117 [M − H]−. The IR
spectra showed a broad absorption band in the range 3019−
2797 cm−1 (v-shaped) along with absorptions at 1736 and
1725 cm−1, suggesting the presence of two OC-OR
moieties, one of them being a carboxyl functional group (R
= H). These findings were corroborated by the 13C NMR
signals at δC 175.1 (broad) and 174.7 and account for the two
degrees of unsaturation. The 2D HSQC-edited spectrum
showed that the remaining 13 carbon atoms consisted of one
CH3, 10 CH2, and two CH (Table 1). The structure
assignment was based on the analysis of the correlations
observed in the 2D HMBC, HSQC-edited, and COSY NMR
spectra. The methine C-2, C-6′ and methylene carbons C-2′,
C-12′ were easily identified on the basis of their chemical
shifts. Key connections deduced from the HMBC and COSY
spectra were used to establish the connectivity along the
carbon skeleton and are shown in Figure 2. Starting with the
HMBC spectrum, the doublet at δ 1.46 (J = 7.2 Hz) of the
methyl group H3-3 showed three correlations with the methine
carbon C-2 at δC 70.3 and with the two carbonyl carbons C-1/
C-1′ at δC 175.1/174.7. The correlation of the methylene
protons H-2′ (multiplet, δH 2.4) with the most shielded signal
indicated that it belongs to C-1′ (δC 174.7). H-2′ also
correlated with C-3′ (δC 25.4) and C-4′ (δC 27.0). The
distinction between the two carbons was achieved through the
identification of H-3′ (m, δH 1.65) via its COSY correlation
with H-2′ and the subsequent HSQC correlation of H-3′ with
the carbon atom to which it is directly bonded. The same
strategy was applied to assign the three methylene groups at
the other end of the molecule. The triplet at δH 3.56 (J = 6.7
Hz) resulting from the protons H-12′ correlated with C-10′
(δC 27.8) and C-11′ (δC 33.7) in the HMBC spectrum. The
latter was assigned based on the H-12′, H-11′ (m, δH 1.77) and
H-11′, C-11′ correlations observed in the COSY and HSQC
spectra, respectively. The carbons at position C-10′ and C-11′
also showed correlations with the diastereotopic protons H-
9a′/H-9b′ (m, δH 1.37 and 1.35), which in turn correlated with
two additional carbon atoms at δC 27.4 and 39.5. They must
correspond to C-8′ and C-7′, respectively. This assignment was
supported by the COSY correlations of H-6′ (m, δH 3.93) with
H-5a′/H-7a′ and H-5b′/H-7b′ (m, δ 1.77 and 1.69). Once the
carbon skeleton was assigned, the correlations observed in the
HSQC spectrum provided the identification of the protons
attached to each carbon atom (Table 1).
An analogous assignment strategy was applied to the
elucidation of the structures of compounds 2, 3, and 4
(Table 1). They showed the same molecular skeleton as
compound 1, only differing in the number and/or position of
the chlorine atoms bound to the lauryl moiety. Chlorosphaer-
olactylate B (2) and chlorosphaerolactylate C (3) were isolated
together as an oil. They are positional isomers of molecular
formula C15H27ClO4 with an HRESIMS peak at m/z
305.1504/305.1509 [M − H]− for 2/3. The position of the
chlorine atom in each compound was easily determined
through the analysis of the 1D and 2D NMR spectroscopic
data. For compound 2, six methylene protons appeared
overlapped in the chemical shift range of δH 1.30−1.37. The
correlations originating from the well-resolved signals of the
methylene groups at positions 2′ (H-2′, δH 2.37, m; C-2′ δC
34.9) and 12′ (H-12′, δH 3.55, t, J = 6.6 Hz; C-12′ δC 45.7)
provided the connectivity along the fragments C-2′−C-5′ and
C-12′−C-9′, respectively. However, the overlap of signals in
the 1H and 13C NMR spectra of the methylene groups 6′ to 8′
prevented their unequivocal assignment. As in compound 1,
the distinguishing feature of the chlorine substituent at C-6′
(H-6′, δH 3.92, m; C-6′ δC 64.9) of compound 3 allowed for
the proper assignment of the neighboring methylene groups
(Table 1). Compound 4 (chlorosphaerolactylate D) was an oil.
The HRESIMS spectrum showed a peak at m/z = 373.0707
[M − H]− consistent with a molecular formula of
C15H25Cl3O4. Two of the three chlorine atoms are bound to
the terminal carbon of the lauric acid chain, as evidenced by
the 1H (H-12′, δH 5.99, t, J = 6.1 Hz) and 13C (C-12′ δC 75.0)
chemical shifts. The location of the third chlorine atom at C-6′
Figure 2. Key COSY and HMBC correlations of chlorosphaer-
olactylate A (1).
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(H-6′, δH 3.94, m; C-6′ δC 64.8) was achieved through the
observation in the HMBC and COSY NMR spectra of the
same set of correlations with neighboring protons as those
described above for compound 1 (Figure 2).
The absolute configuration of C-2 was only established for
chlorosphaerolactylate A (1), due to the available amounts.
Compound 1 was hydrolyzed under acidic conditions, and
through chiral-phase HPLC analysis its lactic acid unit was
determined as L-lactic acid (Figures S32 and S33), allowing the
assignment of the stereocenter at C-2 as 2S. Further
biosynthetic investigations or synthetic studies will be key to
ascertain the configuration at C-6′.
Besides the halogenation found in these new metabolites,
they relate closely to commercial lactylates, which are widely
used as emulsifying agents in the food and cosmetic industries.
In general, lactylates are considered to have nontoxic effects to
humans, as well as biodegradable properties, making them very
interesting for industrial applications.19−22 Given the bio-
technological potential of our findings, attention was directed
to the minor components of fractions F31−F48 (Figure 1).
Hence, further HRESIMS analysis pinpointed the putative
existence of other compounds as bislactylates of chlorinated
(mono-, di-, and tri-) fatty acids (Table S1, Figures S24−S31).
Compounds 1 and 4 as well as a mixture of compounds 2/3
(51:33 ratio) were tested for antibacterial and antifungal
activities using resistant strains derived from clinical isolates:
Escherichia coli AR, S. aureus S54F9,18 and Candida parapsilosis
SMI416.23 The compounds showed a weak antibacterial effect
(2.7−6.0 mM) against S. aureus S54F918 and Candida
parapsilosis SMI416 (Table S2). The same was observed
regarding the antibiofilm activity (0.5−1.1 mM) against
coagulase-negative S. hominis FI31, a clinical isolate collected
from an infected prosthesis (Table S2). The reduction of
activity observed upon the purification process might be
attributed to the effect of the multiple constituents present in
the extract and fractions. For instance, other bioactive
molecules were identified in the methanolic extract, such as
palmitoleic acid and glycerolipids (both showing antibacterial
bioactivity). Moreover, the mixture of lactylates and
bislactylates of chlorinated fatty acids in the bioactive fractions
(Figure 1) might explain the higher antibacterial activity of
fractions versus isolated compounds.
Concerning the antibacterial effects of lactylates, most of
what is found in the literature arises from patents. For instance,
the patent document WO2018222184A124 refers to anti-
microbial compositions, which include sodium isostearyl
lactylate, sodium caproyl/lauroyl lactylate, and sodium lauroyl
lactylate, for inhibiting microbial growth in personal care
products. Likewise, compositions with fatty acid esters as the
predominant component were the subject of the
US6878757B225 patent as an antimicrobial coating for
absorbable surgical materials. Furthermore, the patent docu-
ment US7973006B226 describes the use of an antibacterial
agent (composed of mono- and/or dilactylate esters of
octanoic acid, decanoic acid, dodecanoic acid, tetradecanoic
acid, palmitic acid, or oleic acid) against Gram-negative
bacteria (E. coli, Salmonella sp., Pseudomonas sp., or
Campylobacter sp.).
In conclusion, this study describes the structure of four new
chlorosphaerolactylates, isolated from the cyanobacterium
Sphaerospermopsis sp. LEGE 00249, with weak antibiofilm
and antibacterial and antifungal properties. In addition, other
putative chlorosphaero(bis)lactylates were detected by LC-MS
analysis. These findings taken together add to the knowledge
of the fascinating world of cyanobacterial secondary metabo-
lites, namely, to the class of halogenated fatty acid derivatives.
■ EXPERIMENTAL SECTION
General Experimental Procedures. Optical rotation was
obtained using a P-2000 polarimeter (JASCO). The infrared spectrum
was collected on a Nicolet iS5 FTIR spectrometer (ThermoScien-
tific). The 1D and 2D NMR spectrometric data were measured on a
Bruker AV600 spectrometer equipped with a 5 mm 1H, 13C, 15N, 31P
cryoprobe working at a 1H frequency of 600.13 MHz and 13C
frequency of 150.9 MHz. NMR samples were prepared by dissolving
the fraction in 0.5 mL of CD3OD and transferring the solution to a 5
mm NMR tube. The structure elucidation was based on the analysis
of a set of 1D and 2D NMR spectra including 1H, gNOESY−1H
(water suppression), 13C, COSY, HSQC-edited, and HMBC. 1H and
13C chemical shifts are expressed in δ (ppm) referenced to the solvent
used (CD3OD δH 3.31, 4.87 and δC 49.0). Standard Bruker software
(TopSpin 3.6) was used for the acquisition and processing of the 1D
and 2D NMR spectra.
Cyanobacterial Strain and Culture Conditions. The cyano-
bacterium strain Sphaerospermopsis sp. LEGE 00249 was obtained
from LEGE-CC27 (accession number: KC989701, 16S rRNA gene).
The detection of compounds was performed using biomass of cultures
grown in laboratory conditions. The strain was cultured up to 50 L in
Z8 medium28 at 25 °C, with constant aeration with a photoperiod of
14 h/10 h light and dark, respectively, and at a light intensity of 10−
30 μmol photons s−1 m−2. At the exponential phase, cells were
harvested through centrifugation, then frozen and freeze-dried. In
order to obtain a larger amount of biomass from Sphaerospermopsis sp.
LEGE 00249 that could allow the isolation and chemical character-
ization of compounds 1−4, the culture was scaled-up in outdoor
conditions. In this context, the strain was cultivated in a modified
BG11 medium,29 in which nutrients were added according to growth,
and gradually adapted to outdoor conditions in particular with regard
to light intensity and photoperiod using as culture vessel a 7 L
bubbled tube placed outdoors. A volume containing 15 g of dry
biomass was then transferred to a 40 L GWP-III photobioreactor30 in
order to start with an initial biomass concentration of 20 g m−2 of
reactor illuminated surface. For the first days, the photobioreactor was
tilted backward (north facing) to reduce the light intercepted and thus
reduce light stress to the culture; then it was tilted (50°) facing south
to increase light availability and thus maximize growth and
productivity. The culture was kept at a maximum temperature of 28
°C by circulating cold water inside a stainless-steel serpentine placed
within the culture chamber, and it was bubbled with air at a flow rate
of 0.3 L min−1. Pure CO2 was injected when the pH value exceeded
7.8. The culture was first managed in batch and then in
semicontinuous mode with a 30% daily dilution. In the latter culture
regime, the biomass productivity was 7.6 ± 3.0 g m−2 of reactor
illuminated surface per day with a solar radiation of 29.6 ± 0.3 MJ
m−2 day−1. The culture was harvested at the steady state by
centrifugation, and the biomass frozen and lyophilized prior to use for
the following experiments.
Bioactivity-Guided Fractionation and LC-MS Analysis of the
Antibiotic Fractions. The procedure is supplied in the Supporting
Information.
Consecutive Isolation of Compounds 1−4. The lyophilized
biomass obtained from the scaled-up culture (29.3 g) was sequentially
extracted with hexane, EtOH, and MeOH (Figure S3A). The
resultant extracts were joined, yielding 4.4 g, then fractionated by
normal-phase VLC (Si gel 60, 0.015−0.040 mm, Merck KGaA) using
an increasing polarity grade, with mixtures of n-hexane/EtOAc (9:1 to
0:1), EtOAc/MeOH (7:3), and MeOH, giving a total of nine
fractions. The last fraction eluted with MeOH, which revealed the
presence of lactylates of chlorinated fatty acids by LC-MS analysis,
was further processed through several chromatographic steps using
reversed-phase column chromatography (EMD Millipore silica gel 60
RP-18) with a gradient of H2O/MeOH (from 1:1 to 0:1). The
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isolation of compounds 1 (5.4 mg), 2 (1.1 mg), 3 (1.1 mg), and 4
(1.9 mg), with purity ranging from 29% to 84%, was finalized using
the retention time in the LC-MS instrument using isocratic
conditions, H2O/MeCN, 2:3, both with 0.1% formic acid (Figures
S4−S6).
In order to obtain a larger amount of purer compounds, the
lyophilized biomass obtained from the culture scaled up in outdoor
conditions (400 g, d.w.) was sequentially extracted with MeOH (8 ×
4 L). The resultant extract (134 g) was fractionated by normal-phase
VLC (Si gel 60, 0.015−0.040 mm, Merck KGaA) using an increasing
polarity grade, with mixtures of n-hexane/EtOAc (9:1 to 0:1),
EtOAc/MeOH (7:3), and MeOH, yielding a total of nine fractions.
The two last fractions eluted with EtOAc/MeOH (7:3) and MeOH
revealed the presence of lactylates of chlorinated fatty acids (Figure
S3B) and were then further processed using reversed-phase column
chromatography (EMD Millipore silica gel 60 RP-18) with gradients
of H2O/MeOH (from 1:1 to 0:1) with 0.1% formic acid. An ion-
exchange preparative step (Strata SAX SPE tubes, 20 g/60 mL,
Phenomenex) was performed before the final purification, carried out
with the time-based automatic collector of a Waters Alliance e2695
HPLC instrument coupled with a PDA (photodiode array) detector.
The yields obtained for this second batch were as follows: 1 (5.4 mg),
4 (2.9 mg), purity >90%, and mixture 2/3 (1.8 mg; 51:33 ratio of
both compounds, 84% pure).
Chlorosphaerolactylate A (2S-[(6,12-dichlorododecanoyl)oxy]-
propanoic acid) (1): oil; [α]24D +33 (c 0.01, MeOH); IR (KBr)
νmax 2937, 1736, and 1725 cm
−1; 1H and 13C NMR spectroscopic data
(CD3OD), Table 1; HRMS m/z 339.1117 [M − H]− (calcd for
C15H26Cl2O4, 339.1135).
Chlorosphaerolactylate B ([(12-chlorododecanoyl)oxy]-
propanoic acid) (2): oil; 1H and 13C NMR spectroscopic data
(CD3OD), Table 1; HRMS m/z 305.1504 [M − H]− (calcd for
C15H27ClO4, 305.1525).
Chlorosphaerolactylate C ([(6-chlorododecanoyl)oxy]propanoic
acid) (3). oil; 1H and 13C NMR spectroscopic data (CD3OD), Table
1; HRMS m/z 305.1509 [M − H]− (calcd for C15H27ClO4,
305.1525).
Chlorosphaerolactylate D ([(6,12,12-trichlorododecanoyl)oxy]-
propanoic acid) (4): oil; 1H and 13C NMR spectroscopic data
(CD3OD), Table 1; HRMS m/z 373.0707 [M − H]− (calcd for
C15H25Cl3O4, 373.0746).
Acid Hydrolysis of 1 and Chiral-Phase HPLC. Chlorosphaer-
olactylate A (1, 1 mg) was hydrolyzed in 1 mL of 0.5 N HCl solution
in H2O/MeCN (1:9), at room temperature during 3 h, and afterward
the solution was concentrated under vacuum. The hydrolysate and the
L-(+)- and D-(−)-lactic acid standards (Santa Cruz Biotechnology)
were dissolved in H2O (0.5 mg/mL) and eluted through a chiral-
phase column, Chirex 3126 (D)-penicillamine (50 × 4.6 mm,
Phenomenex), using a 2 mM CuSO4/H2O solution, at a flow rate
of 1 mL/min. The chromatograms at 245 nm of the hydrolysate were
compared with the standards L- and D-lactic acid (Figures S32 and
S33).
Bacterial Strains and Culture Conditions. E. coli clinical isolate
(AR-collected from urine at the Hospital Clinic of Barcelona), S.
aureus spa type t1333 (S54F9),18 and C. parapsilosis clinical isolate
from a bloodstream infection (SMI416)23 were employed for
antibacterial and antifungal activities. E. coli, S. aureus, and C.
parapsilosis were resuscitated on MH agar (Mueller-Hinton Agar,
Oxoid) at 37 °C from 25% glycerol (v/v) stocks kept at −20 °C and
maintained thereafter at 4 °C. Coagulase-negative S. hominis FI31 is a
clinical isolated collected from an infected prosthesis at the Hospital
Clinic of Barcelona. Bacterial culture media were purchased from
ThermoScientific. All other solutions and media were made with
ultrapure deionized water and were sterilized by autoclaving at 121 °C
for 15 min.
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Centre CIAIMBITAL, Universidad de Almeriá, 04120, Spain;
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(10) Jimeńez, J. I.; Vansach, T.; Yoshida, W. Y.; Sakamoto, B.;
Pörzgen, P.; Horgen, F. D. J. Nat. Prod. 2009, 72 (9), 1573−1578.
(11) Lopez, J. A. V.; Petitbois, J. G.; Vairappan, C. S.; Umezawa, T.;
Matsuda, F.; Okino, T. Org. Lett. 2017, 19 (16), 4231−4234.
(12) Moore, R. E.; Bornemann, V.; Niemczura, W. P.; Gregson, J.
M.; Chen, J. L.; Norton, T. R.; Patterson, G. M. L.; Helms, G. L. J.
Am. Chem. Soc. 1989, 111 (16), 6128−6132.
(13) Luesch, H.; Yoshida, W. Y.; Moore, R. E.; Paul, V. J.; Mooberry,
S. L. J. Nat. Prod. 2000, 63 (5), 611−615.
(14) Mercer, E. I.; Davies, C. L. Phytochemistry 1975, 14 (7), 1545−
1548.
(15) Moosmann, P.; Ueoka, R.; Gugger, M.; Piel, J. Org. Lett. 2018,
20 (17), 5238−5241.
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